TY - JOUR
T1 - High Incidence of Afebrile Bloodstream Infection Detected by Surveillance Blood Culture in Patients on Corticosteroid Therapy after Allogeneic Hematopoietic Stem Cell Transplantation
AU - Kameda, Kazuaki
AU - Kimura, Shun ichi
AU - Akahoshi, Yu
AU - Nakano, Hirofumi
AU - Harada, Naonori
AU - Ugai, Tomotaka
AU - Wada, Hidenori
AU - Yamasaki, Ryoko
AU - Ishihara, Yuko
AU - Kawamura, Koji
AU - Sakamoto, Kana
AU - Ashizawa, Masahiro
AU - Sato, Miki
AU - Terasako-Saito, Kiriko
AU - Nakasone, Hideki
AU - Kikuchi, Misato
AU - Yamazaki, Rie
AU - Kanda, Junya
AU - Kako, Shinichi
AU - Tanihara, Aki
AU - Nishida, Junji
AU - Kanda, Yoshinobu
N1 - Funding Information:
This work was presented in part at the 37th Annual Meeting of the Japan Society for Hematopoietic Cell Transplantation, Kobe, Japan, 2015 (Abstract O18-3). Financial disclosure: The authors have nothing to disclose. Conflict of interest statement: We have no conflict of interest for this study.
Publisher Copyright:
© 2016 American Society for Blood and Marrow Transplantation.
PY - 2016/2/1
Y1 - 2016/2/1
N2 - Bloodstream infections (BSI) are still important complications after allogeneic hematopoietic stem cell transplantation (allo-SCT). Patients who are receiving corticosteroid therapy can develop BSI without fever. The utility of surveillance blood cultures in these situations is controversial. We retrospectively analyzed 74 patients who received a corticosteroid consisting of ≥.5 mg/kg prednisolone or equivalent after allo-SCT. In principle, we performed surveillance blood culture weekly for these patients. Sixteen patients (21.6%) developed definite BSI. In a multivariate analysis, a myeloablative conditioning regimen, high-risk disease status at allo-SCT, and the presence of a central venous catheter at the initiation of corticosteroid therapy were identified as independent significant risk factors for the development of definite BSI. At the first definite BSI episode, 7 patients (46.7%) were afebrile and diagnosed by surveillance blood culture. However, 6 of these 7 afebrile patients showed various signs that could be attributed to infection at the time of positive blood culture. In conclusion, patients receiving corticosteroid therapy after allo-SCT frequently develop afebrile BSI. Although surveillance blood culture might be beneficial in these situations, it also seems important to not miss the signs of BSI, even when patients are afebrile.
AB - Bloodstream infections (BSI) are still important complications after allogeneic hematopoietic stem cell transplantation (allo-SCT). Patients who are receiving corticosteroid therapy can develop BSI without fever. The utility of surveillance blood cultures in these situations is controversial. We retrospectively analyzed 74 patients who received a corticosteroid consisting of ≥.5 mg/kg prednisolone or equivalent after allo-SCT. In principle, we performed surveillance blood culture weekly for these patients. Sixteen patients (21.6%) developed definite BSI. In a multivariate analysis, a myeloablative conditioning regimen, high-risk disease status at allo-SCT, and the presence of a central venous catheter at the initiation of corticosteroid therapy were identified as independent significant risk factors for the development of definite BSI. At the first definite BSI episode, 7 patients (46.7%) were afebrile and diagnosed by surveillance blood culture. However, 6 of these 7 afebrile patients showed various signs that could be attributed to infection at the time of positive blood culture. In conclusion, patients receiving corticosteroid therapy after allo-SCT frequently develop afebrile BSI. Although surveillance blood culture might be beneficial in these situations, it also seems important to not miss the signs of BSI, even when patients are afebrile.
KW - Allogeneic hematopoietic stem cell transplantation
KW - Bloodstream infection
KW - Corticosteroid
KW - Surveillance blood culture
UR - http://www.scopus.com/inward/record.url?scp=84958652401&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84958652401&partnerID=8YFLogxK
U2 - 10.1016/j.bbmt.2015.09.019
DO - 10.1016/j.bbmt.2015.09.019
M3 - Article
C2 - 26415560
AN - SCOPUS:84958652401
SN - 1083-8791
VL - 22
SP - 371
EP - 377
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
IS - 2
ER -